Screener
Supernus Pharmaceuticals SUPN Compensation and benefits
Compensation and benefits at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Amortization of premium/discount on marketable securities | (192) | (1,074) |
| Change in fair value of contingent consideration | 2,391 | 7,660 |
| Realized loss (gain) from sale of marketable securities | (21) | 9 |
| Share-based compensation expense | 8,480 | 8,068 |
| Deferred income tax expense (benefit) | 5,916 | (3,990) |
| Noncash lease expense | 2,258 | 1,341 |
| Inventory valuation write-down | 1,815 | 547 |
| Payment of contingent consideration | — | (4,900) |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Supernus Pharmaceuticals's compensation and benefits?
- Supernus Pharmaceuticals (SUPN) reported compensation and benefits of $8.48M in Q1 2026.
- What does compensation and benefits mean?
- Total employee-related costs including salaries, wages, bonuses, commissions, stock-based compensation, health insurance, retirement contributions, and payroll taxes.
Ask your AI about Supernus Pharmaceuticals's compensation and benefits.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude